Rob Etherington is the President and CEO of Clene – a clinical stage biopharmaceutical company. Clene’s goal is to create the first drug asset to improve neurological function and strives to create assets to help those with ALS, multiple sclerosis, and Parkinson’s Disease. Clene will know by the end of 2021 if their new asset can be used to treat all three of these diseases. Listen to learn more about this company and Rob’s various roles as the CEO of a biopharmaceutical company.